YIH
LYRA

Y-Intercept (HK)’s LYRA THERAPEUTICS INC LYRA Stock Holding History

Y-Intercept (HK)’s Portfolio LYRA Stock Details LYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-550
Closed -$7.61K – 1591
2024
Q2 		$7.61K Buy
550
+139
+34% +$15.7K ﹤0.01% 1321
2024
Q1 		$128K Buy
411
+165
+67% +$44K 0.01% 1245
2023
Q4 		$64.3K Buy
+246
New +$44.5K 0.01% 1139

Other funds holding LYRA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SEI Investments
SEI Investments Oaks, Pennsylvania $108B AUM 26.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Y-Intercept (HK)'s LYRA Position: Q3 2024 in Review

Y-Intercept (HK) sold out of LYRA THERAPEUTICS INC (LYRA) in Q3 2024, closing a stake of 550 shares — an estimated $7.61K sold.

Y-Intercept (HK) first reported a position in LYRA in Q4 2023 and held it in 3 quarters. The position peaked at $128K in Q1 2024. 62 funds tracked by Wall St. Rank hold LYRA as of Q3 2024.

  • Y-Intercept (HK) reported no remaining LYRA THERAPEUTICS INC position as of Q3 2024 after selling out during the quarter.
  • Y-Intercept (HK) sold 550 LYRA THERAPEUTICS INC shares in Q3 2024, an estimated $7.61K.
  • Y-Intercept (HK) first reported a position in LYRA THERAPEUTICS INC in Q4 2023 and held it in 3 quarters.
  • Y-Intercept (HK)'s LYRA THERAPEUTICS INC position peaked at $128K in Q1 2024.
  • 62 funds tracked by Wall St. Rank held LYRA THERAPEUTICS INC as of Q3 2024.

Based on Y-Intercept (HK)'s 13F filing for Q3 2024, filed 15 Nov 2024.